{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:17:45Z","timestamp":1793157465532,"version":"4.5.0"},"reference-count":61,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,8,28]]},"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Concomitant medications, such as steroids, proton pump inhibitors (PPI) and antibiotics, might affect clinical outcomes with immune checkpoint inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a multicenter observational retrospective study aimed at evaluating the impact of concomitant medications on clinical outcomes, by weighing their associations with baseline clinical characteristics (including performance status, burden of disease and body mass index) and the underlying causes for their prescription. This analysis included consecutive stage IV patients with cancer, who underwent treatment with single agent antiprogrammed death-1\/programmed death ligand-1 (PD-1\/PD-L1) with standard doses and schedules at the medical oncology departments of 20 Italian institutions. Each medication taken at the immunotherapy initiation was screened and collected into key categories as follows: corticosteroids, antibiotics, gastric acid suppressants (including proton pump inhibitors - PPIs), statins and other lipid-lowering agents, aspirin, anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs), ACE inhibitors\/Angiotensin II receptor blockers, calcium antagonists, \u03b2-blockers, metformin and other oral antidiabetics, opioids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From June 2014 to March 2020, 1012 patients were included in the analysis. Primary tumors were: non-small cell lung cancer (52.2%), melanoma (26%), renal cell carcinoma (18.3%) and others (3.6%). Baseline statins (HR 1.60 (95% CI 1.14 to 2.25), p=0.0064), aspirin (HR 1.47 (95% CI 1.04 to 2.08, p=0.0267) and \u03b2-blockers (HR 1.76 (95% CI 1.16 to 2.69), p=0.0080) were confirmed to be independently related to an increased objective response rate. Patients receiving cancer-related steroids (HR 1.72 (95% CI 1.43 to 2.07), p&lt;0.0001), prophylactic systemic antibiotics (HR 1.85 (95% CI 1.23 to 2.78), p=0.0030), prophylactic gastric acid suppressants (HR 1.29 (95% CI 1.09 to 1.53), p=0.0021), PPIs (HR 1.26 (95% CI 1.07 to 1.48), p=0.0050), anticoagulants (HR 1.43 (95% CI: 1.16 to 1.77), p=0.0007) and opioids (HR 1.71 (95% CI 1.28 to 2.28), p=0.0002) were confirmed to have a significantly higher risk of disease progression. Patients receiving cancer-related steroids (HR 2.16 (95% CI 1.76 to 2.65), p&lt;0.0001), prophylactic systemic antibiotics (HR 1.93 (95% CI 1.25 to 2.98), p=0.0030), prophylactic gastric acid suppressants (HR 1.29 (95% CI 1.06 to 1.57), p=0.0091), PPI (HR 1.26 (95% CI 1.04 to 1.52), p=0.0172), anticoagulants (HR 1.45 (95% CI 1.14 to 1.84), p=0.0024) and opioids (HR 1.53 (95% CI 1.11 to 2.11), p=0.0098) were confirmed to have a significantly higher risk of death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We confirmed the association between baseline steroids administered for cancer-related indication, systemic antibiotics, PPIs and worse clinical outcomes with PD-1\/PD-L1 checkpoint inhibitors, which can be assumed to have immune-modulating detrimental effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2020-001361","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T16:08:59Z","timestamp":1604592539000},"page":"e001361","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":242,"title":["Integrated analysis of concomitant medications and oncological outcomes from PD-1\/PD-L1 checkpoint inhibitors in clinical practice"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1209-5735","authenticated-orcid":false,"given":"Alessio","family":"Cortellini","sequence":"first","affiliation":[{"name":"Department of Biotechnology and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy"},{"name":"Medical Oncology, St. Salvatore Hospital, L'Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Tucci","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Department of Biomedical Sciences and Human Oncology, University of Bari, Bary, Italy"},{"name":"National Cancer Research Center, Tumori Institute IRCCS Giovanni Paolo II, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Adamo","sequence":"additional","affiliation":[{"name":"Medical Oncology, Department of Human Pathology, A.O. Papardo, University of Messina, Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigia Stefania","family":"Stucci","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Department of Biomedical Sciences and Human Oncology, University of Bari, Bary, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Russo","sequence":"additional","affiliation":[{"name":"Medical Oncology, Department of Human Pathology, A.O. Papardo, University of Messina, Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica Teresa","family":"Tanda","sequence":"additional","affiliation":[{"name":"IRCCS Ospedale Policlinico San Martino, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Spagnolo","sequence":"additional","affiliation":[{"name":"IRCCS Ospedale Policlinico San Martino, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Rastelli","sequence":"additional","affiliation":[{"name":"Medical Oncology, ASUR District Area 4 Fermo, Fermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Bisonni","sequence":"additional","affiliation":[{"name":"Medical Oncology, ASUR District Area 4 Fermo, Fermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[{"name":"Medical Oncology, Campus Bio-Medico University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Russano","sequence":"additional","affiliation":[{"name":"Medical Oncology, Campus Bio-Medico University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Anesi","sequence":"additional","affiliation":[{"name":"Medical Oncology, Campus Bio-Medico University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Giusti","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Sant'Andrea Hospital of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Filetti","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Sant'Andrea Hospital of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Marchetti","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Sant'Andrea Hospital of Rome, Rome, Italy"},{"name":"Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy"},{"name":"Medical Oncology Unit B, Policlinico Umberto I, Sapienza University of Rome, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Botticelli","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Gelibter","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit B, Policlinico Umberto I, Sapienza University of Rome, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Alberto","family":"Occhipinti","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit B, Policlinico Umberto I, Sapienza University of Rome, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Marconcini","sequence":"additional","affiliation":[{"name":"Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giuseppa","family":"Vitale","sequence":"additional","affiliation":[{"name":"Medical Oncology, University Hospital Modena, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Nicolardi","sequence":"additional","affiliation":[{"name":"UOC Oncologia Padova Sud, Azienda ULSS 6 Euganea, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Chiari","sequence":"additional","affiliation":[{"name":"UOC Oncologia Padova Sud, Azienda ULSS 6 Euganea, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Bareggi","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore di Milano Policlinico, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Nigro","sequence":"additional","affiliation":[{"name":"Medical Oncology, ASST Sette Laghi, Ospedale di Circolo e Fondazione Macchi, Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Tuzi","sequence":"additional","affiliation":[{"name":"Medical Oncology, ASST Sette Laghi, Ospedale di Circolo e Fondazione Macchi, Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"De Tursi","sequence":"additional","affiliation":[{"name":"Department of Medical, Oral and Biotechnological Sciences, Gabriele d'Annunzio University of Chieti and Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Petragnani","sequence":"additional","affiliation":[{"name":"Department of Psychological, Health and Territorial Sciences, University G. D'Annunzio of Chieti and Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Pala","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology for Melanoma, Sarcoma and Rare Tumors, IEO European Institute of Oncology IRCCS, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Bracarda","sequence":"additional","affiliation":[{"name":"Medical Oncology, Azienda Ospedaliera S. Maria, Terni, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Macrini","sequence":"additional","affiliation":[{"name":"Medical Oncology, Azienda Ospedaliera S. Maria, Terni, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Inno","sequence":"additional","affiliation":[{"name":"Oncology Unit, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Zoratto","sequence":"additional","affiliation":[{"name":"Medical Oncology, Santa Maria Goretti Hospital, Latina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enzo","family":"Veltri","sequence":"additional","affiliation":[{"name":"Medical Oncology, Santa Maria Goretti Hospital, Latina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Di Cocco","sequence":"additional","affiliation":[{"name":"Medical Oncology, Santa Maria Goretti Hospital, Latina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Mallardo","sequence":"additional","affiliation":[{"name":"Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione \"G. Pascale\", Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Vitale","sequence":"additional","affiliation":[{"name":"Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione \"G. Pascale\", Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3529-0103","authenticated-orcid":false,"given":"David James","family":"Pinato","sequence":"additional","affiliation":[{"name":"Division of Cancer, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Porzio","sequence":"additional","affiliation":[{"name":"Medical Oncology, St. Salvatore Hospital, L'Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Ficorella","sequence":"additional","affiliation":[{"name":"Department of Biotechnology and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy"},{"name":"Medical Oncology, St. Salvatore Hospital, L'Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-475X","authenticated-orcid":false,"given":"Paolo Antonio","family":"Ascierto","sequence":"additional","affiliation":[{"name":"Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione \"G. Pascale\", Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,11,5]]},"reference":[{"key":"2025100310104422000_8.2.e001361.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1887"},{"key":"2025100310104422000_8.2.e001361.2","first-page":"1","article-title":"Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?","author":"Hussain","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"2025100310104422000_8.2.e001361.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.015"},{"key":"2025100310104422000_8.2.e001361.4","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00262-004-0577-x","article-title":"Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape?","volume":"53","author":"Malmberg","year":"2004","journal-title":"Cancer Immunol Immunother"},{"key":"2025100310104422000_8.2.e001361.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0006"},{"key":"2025100310104422000_8.2.e001361.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00189"},{"key":"2025100310104422000_8.2.e001361.7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030546","article-title":"Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"12","author":"Petrelli","year":"2020","journal-title":"Cancers"},{"key":"2025100310104422000_8.2.e001361.8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy103"},{"key":"2025100310104422000_8.2.e001361.9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.annonc.2020.01.006","article-title":"Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the oak and poplar trials","volume":"31","author":"Chalabi","year":"2020","journal-title":"Ann Oncol"},{"key":"2025100310104422000_8.2.e001361.10","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1001\/jamaoncol.2019.2785","article-title":"Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer","volume":"5","author":"Pinato","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100310104422000_8.2.e001361.11","doi-asserted-by":"crossref","first-page":"x40","DOI":"10.1093\/annonc\/mdy511.001","article-title":"Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients","volume":"29","author":"Homicsko","year":"2018","journal-title":"Ann Oncol"},{"key":"2025100310104422000_8.2.e001361.12","doi-asserted-by":"crossref","first-page":"e602","DOI":"10.1634\/theoncologist.2019-0518","article-title":"The impact of nonsteroidal anti-inflammatory drugs, beta blockers, and metformin on the efficacy of anti-PD-1 therapy in advanced melanoma","volume":"25","author":"Wang","year":"2020","journal-title":"Oncologist"},{"key":"2025100310104422000_8.2.e001361.13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2217\/imt-2019-0064","article-title":"Impact of concomitant medication use and immune-related adverse events on response to immune checkpoint inhibitors","volume":"12","author":"Gandhi","year":"2020","journal-title":"Immunotherapy"},{"key":"2025100310104422000_8.2.e001361.14","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1007\/s00432-020-03252-4","article-title":"Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1\/PD-L1 antibody-based immunotherapy","volume":"146","author":"Hakozaki","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025100310104422000_8.2.e001361.15","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0527-y"},{"key":"2025100310104422000_8.2.e001361.16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2019.12.031","article-title":"Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)\/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: a multicentre analysis of immune-related adverse events","volume":"128","author":"Cortellini","year":"2020","journal-title":"Eur J Cancer"},{"key":"2025100310104422000_8.2.e001361.17","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1710389","article-title":"Evaluating the role of family history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1\/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study","volume":"9","author":"Cortellini","year":"2020","journal-title":"Oncoimmunology"},{"key":"2025100310104422000_8.2.e001361.18","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-019-02132-x","article-title":"Early fatigue in cancer patients receiving PD-1\/PD-L1 checkpoint inhibitors: an insight from clinical practice","volume":"17","author":"Cortellini","year":"2019","journal-title":"J Transl Med"},{"key":"2025100310104422000_8.2.e001361.19","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0618"},{"key":"2025100310104422000_8.2.e001361.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2019.02.006"},{"key":"2025100310104422000_8.2.e001361.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025100310104422000_8.2.e001361.22","unstructured":"Woolley KK . How variables uncorrelated with the dependent variable can actually make excellent predictors: the important suppressor variable case. Southwest educational research association annual meeting proceedings, 1997. Available: https:\/\/eric.ed.gov\/?id=ED407420 [Accessed 10 Jun 2020]."},{"key":"2025100310104422000_8.2.e001361.23","first-page":"11","article-title":"Examples of easily Explainable suppressor variables in multiple regression research","volume":"24","author":"Thompson","year":"1997","journal-title":"Multi Linear Regres Viewpoints"},{"key":"2025100310104422000_8.2.e001361.24","unstructured":"\u201cStopping stepwise: Why stepwise selection is bad and what you should use instead\u201d. On towardsdatascience.com. Available: https:\/\/towardsdatascience.com\/stopping-stepwise-why-stepwise-selection-is-bad-and-what-you-should-use-instead-90818b3f52df [Accessed 10 Jun 2020]."},{"key":"2025100310104422000_8.2.e001361.25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.juro.2013.08.049","article-title":"Bladder cancer in Spain 2011: population based study","volume":"191","author":"Mi\u00f1ana","year":"2014","journal-title":"J Urol"},{"key":"2025100310104422000_8.2.e001361.26","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1001\/jamadermatol.2013.706","article-title":"Distinctive features of melanoma and its management in elderly patients: a population-based study in France","volume":"149","author":"Ciocan","year":"2013","journal-title":"JAMA Dermatol"},{"key":"2025100310104422000_8.2.e001361.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2015.02.006"},{"key":"2025100310104422000_8.2.e001361.28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/0284186X.2015.1115121","article-title":"Trends in kidney cancer among the elderly in Denmark, 1980-2012","volume":"55(Suppl 1)","author":"Azawi","year":"2016","journal-title":"Acta Oncol"},{"key":"2025100310104422000_8.2.e001361.29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.lfs.2017.11.049","article-title":"Chronic glucocorticoid treatment induced circadian clock disorder leads to lipid metabolism and gut microbiota alterations in rats","volume":"192","author":"Wu","year":"2018","journal-title":"Life Sci"},{"key":"2025100310104422000_8.2.e001361.30","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2019.00978","article-title":"Alterations of the gut microbiota associated with promoting efficacy of prednisone by Bromofuranone in MRL\/lpr mice","volume":"10","author":"He","year":"2019","journal-title":"Front Microbiol"},{"key":"2025100310104422000_8.2.e001361.31","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/aps.2016.70","article-title":"Intestinal Metrnl released into the gut lumen acts as a local regulator for gut antimicrobial peptides","volume":"37","author":"Li","year":"2016","journal-title":"Acta Pharmacol Sin"},{"key":"2025100310104422000_8.2.e001361.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.08.010"},{"key":"2025100310104422000_8.2.e001361.33","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i22.2706"},{"key":"2025100310104422000_8.2.e001361.34","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-310861"},{"key":"2025100310104422000_8.2.e001361.35","doi-asserted-by":"crossref","first-page":"e01358","DOI":"10.1128\/mBio.01358-15","article-title":"Histamine H2 receptor-mediated suppression of intestinal inflammation by probiotic Lactobacillus reuteri","volume":"6","author":"Gao","year":"2015","journal-title":"mBio"},{"key":"2025100310104422000_8.2.e001361.36","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.surg.2011.07.067","article-title":"H2 blockers decrease gut mucus production and lead to barrier dysfunction in vitro","volume":"150","author":"Diebel","year":"2011","journal-title":"Surgery"},{"key":"2025100310104422000_8.2.e001361.37","unstructured":"U.S. Food and Drug Administration . Questions and answers: NDMA impurities in ranitidine (commonly known as Zantac). Available: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/questions-and-answers-ndma-impurities-ranitidine-commonly-known-zantac [Accessed 14 Jun 2020]."},{"key":"2025100310104422000_8.2.e001361.38","unstructured":"European Medicines Agencies . EMA to review ranitidine medicines following detection of NDMA. Available: https:\/\/www.ema.europa.eu\/en\/news\/ema-review-ranitidine-medicines-following-detection-ndma [Accessed 14 Jun 2020]."},{"key":"2025100310104422000_8.2.e001361.39","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-28583-8","article-title":"Anticoagulants impact on innate immune responses and bacterial survival in whole blood models of Neisseria meningitidis infection","volume":"8","author":"Strobel","year":"2018","journal-title":"Sci Rep"},{"key":"2025100310104422000_8.2.e001361.40","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jpain.2017.12.012","article-title":"Revealing a brain-gut microbiome connection following chronic opioid treatment","volume":"19","author":"Taylor","year":"2018","journal-title":"J Pain"},{"key":"2025100310104422000_8.2.e001361.41","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/apt.13858","article-title":"Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis","volume":"45","author":"Acharya","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2025100310104422000_8.2.e001361.42","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2016.9"},{"key":"2025100310104422000_8.2.e001361.43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/FBP.0000000000000538","article-title":"The role of the gut microbiome in opioid use","volume":"31","author":"Ren","year":"2020","journal-title":"Behav Pharmacol"},{"key":"2025100310104422000_8.2.e001361.44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0242"},{"key":"2025100310104422000_8.2.e001361.45","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70112-2"},{"key":"2025100310104422000_8.2.e001361.46","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-017-1150-7"},{"key":"2025100310104422000_8.2.e001361.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.015"},{"key":"2025100310104422000_8.2.e001361.48","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cmet.2019.04.002","article-title":"Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment","volume":"30","author":"Ma","year":"2019","journal-title":"Cell Metab"},{"key":"2025100310104422000_8.2.e001361.49","doi-asserted-by":"publisher","DOI":"10.1038\/nature17412"},{"key":"2025100310104422000_8.2.e001361.50","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061410","article-title":"The pivotal role of the dysregulation of cholesterol homeostasis in cancer: implications for therapeutic targets","volume":"12","author":"Mok","year":"2020","journal-title":"Cancers"},{"key":"2025100310104422000_8.2.e001361.51","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/CJI.0000000000000321","article-title":"The prognostic role of high blood cholesterol in advanced cancer patients treated with immune checkpoint inhibitors","volume":"43","author":"Perrone","year":"2020","journal-title":"J Immunother"},{"key":"2025100310104422000_8.2.e001361.52","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.2908","article-title":"Propranolol for off-label treatment of patients with melanoma: results from a cohort study","volume":"4","author":"De Giorgi","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025100310104422000_8.2.e001361.53","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1405205","article-title":"Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice","volume":"7","author":"Kokolus","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025100310104422000_8.2.e001361.54","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.mehy.2013.08.026","article-title":"Can non-selective beta-blockers prevent hepatocellular carcinoma in patients with cirrhosis?","volume":"81","author":"Thiele","year":"2013","journal-title":"Med Hypotheses"},{"key":"2025100310104422000_8.2.e001361.55","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jamaoncol.2019.5241","article-title":"Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer","volume":"6","author":"Kichenadasse","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025100310104422000_8.2.e001361.56","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0375-1"},{"key":"2025100310104422000_8.2.e001361.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2010.04.005"},{"key":"2025100310104422000_8.2.e001361.58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00604"},{"key":"2025100310104422000_8.2.e001361.59","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0371-5"},{"key":"2025100310104422000_8.2.e001361.60","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-10-57"},{"key":"2025100310104422000_8.2.e001361.61","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2011.11.021"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-001361","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T17:10:59Z","timestamp":1759511459000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-001361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":61,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,11,5]]},"published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1136\/jitc-2020-001361"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-001361","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}